DoD Arthritis, Focused Research Award
ID: 356100Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356100
Timeline
    Description

    The Department of the Army, through the U.S. Army Medical Research Acquisition Activity, is offering the FY24 Arthritis Focused Research Award (FRA) to support innovative research aimed at improving patient care and quality of life for individuals affected by various forms of arthritis, particularly in relation to military personnel. This grant opportunity encourages applications that explore high-risk, potentially high-reward research addressing all types of arthritis, with a focus on the impact of arthritis on military readiness and health. The program has an estimated total funding of $2.5 million, with awards expected to be made by September 30, 2025, and applications must be submitted by October 30, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT9425FY24ATRPFRA_GG.pdf
    The DOD FY24 Arthritis Focused Research Award, managed by the U.S. Army Medical Research Acquisition Activity, provides up to $10 million in funding for innovative research focused on various forms of arthritis, particularly that affecting Service Members' health and retention. Applications are encouraged from extramural and intramural organizations, with important deadlines set for pre-application and application submissions in October 2024. The program emphasizes research areas like prevention, diagnosis, and intervention/treatment of arthritis, and includes two distinct funding levels based on the stage of research proposed: Research Level 1 for exploratory studies and Research Level 2 for preclinical to clinical translation research. The goal is to significantly reduce arthritis' impact on military readiness and wellness. All applications will undergo rigorous peer and programmatic review processes, evaluating criteria like impact, research strategy, and feasibility. Successful proposals are expected to eventually benefit both military and civilian populations. Detailed application guidance, eligibility requirements, and submission protocols are outlined, emphasizing a structured approach to foster collaboration and innovation in arthritis research.
    Similar Opportunities
    BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), has announced a Broad Agency Announcement (BAA) for Extramural Biomedical and Human Performance Research and Development. This opportunity invites unrestricted applicants to submit proposals aimed at advancing biomedical research and development, with a focus on enhancing human performance. The program is critical for fostering innovation in science and technology, particularly in areas that support the Department of Defense's mission. The estimated total program funding is $10 million, with individual awards ranging from $750,000 to $50 million, and proposals are due by July 31, 2028. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    Airman Readiness Medical Research (ARMR) Hybrid BAA
    Active
    Air Force -- Research Lab
    The Air Force Research Laboratory (AFRL) is soliciting proposals for the Airman Readiness Medical Research (ARMR) program through a Hybrid Broad Agency Announcement (BAA) designated FA8650-20-S-6008. The primary objectives of this initiative are to conduct medical research aimed at optimizing the health and performance of Airmen, focusing on ensuring medical availability and understanding the effects of various operational environments on Airman well-being. This program is critical for enhancing the operational readiness of military personnel, particularly in high-demand mission scenarios, with key research areas including aeromedical evacuation, cognitive performance, and exposure health. The total funding available for this program is estimated at $480 million, with individual awards ranging from $50,000 to $49 million. Interested parties are encouraged to submit white papers by May 1, 2025, and can direct inquiries to Amber A. Taylor at amber.taylor.9@us.af.mil.
    Staff Research Program
    Active
    Dept of the Army -- Materiel Command
    The Department of the Army's Materiel Command is offering a funding opportunity through the Staff Research Program, aimed at fostering collaborative basic research between its scientific staff and institutions of higher education. The program seeks to enhance the professional competence of Army Research Office (ARO) scientists by engaging in hands-on research that advances knowledge in various scientific disciplines, including engineering, physical, life, and information sciences. This initiative is crucial for maintaining the integrity of ARO's mission while promoting innovative research aligned with Army interests. Interested applicants must submit proposals via Grants.gov by February 19, 2025, with no cost-sharing requirement, and can direct inquiries to William A. Creech at william.a.creech3.civ@mail.mil or by phone at 919-549-4387.
    NFRP Outreach and Invitation for Response
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), is forecasting an opportunity for a Research-based Other Transactions Agreement (rOTA) under the Neurofibromatosis Research Program (NFRP). This initiative aims to accelerate the clinical translation of basic research related to neurofibromatosis (NF) by conducting collaborative Phase I and II clinical trials focused on promising therapeutic agents for NF1, NF2, and schwannomatosis. Historically, this requirement has been addressed through assistance agreements, and the government is now seeking feedback on this proposed approach, emphasizing the need for cost-sharing arrangements and access to patient populations. Interested parties can direct inquiries to Jason D. Kuhns at jason.d.kuhns.civ@mail.mil, with the opportunity being part of the FY21 portfolio and requiring a demonstrated history of collaborative research among participants.
    Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering Exploratory Clinical Trial Grants (R61) to support research in arthritis and musculoskeletal and skin diseases. This funding opportunity aims to facilitate short-term, interventional studies that address critical research questions, particularly those evaluating drug efficacy in rare diseases, without requiring preliminary data. Grants can provide up to $600,000 over three years, with applications due by November 2, 2026. Interested applicants are encouraged to consult with NIH staff during the application process and can find additional information at NIH Grants or by contacting NIH Grants Information at grantsinfo@nih.gov.
    DOD Glioblastoma, Transformative Consortium Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the FY24 Glioblastoma Transformative Consortium Award, aimed at advancing research to improve outcomes for glioblastoma patients. This grant seeks proposals for innovative, multidisciplinary projects that collectively address a central hypothesis, requiring collaboration among at least four distinct projects and the inclusion of a consumer advocate. With an estimated total program funding of $9 million, the application process includes a pre-application deadline of December 23, 2024, and a full application deadline of January 13, 2025. Interested applicants can reach the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507 for further assistance.
    Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering funding opportunities through the "Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases" program, specifically under the R61 Clinical Trial mechanism. This initiative aims to support short-term exploratory clinical trials that investigate treatments for rheumatic, musculoskeletal, and skin conditions, with a focus on diverse therapeutic approaches. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and state and local governments, with a maximum budget of $600,000 for a three-year project, not exceeding $300,000 in any single year. Applications must be submitted electronically via Grants.gov, with key deadlines starting from February 4, 2024, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov. For more details, visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-035.html.
    DEVCOM ARMY RESEARCH LABORATORY BROAD AGENCY ANNOUNCEMENT FOR FOUNDATIONAL RESEARCH
    Active
    Dept of the Army -- Materiel Command
    The Department of the Army, through the U.S. Army Combat Capabilities Development Command (DEVCOM) Army Research Laboratory (ARL), has issued a Broad Agency Announcement (BAA) for foundational research aimed at enhancing Army capabilities from November 21, 2022, to November 20, 2027. This opportunity invites innovative research proposals from a diverse range of eligible applicants, including institutions of higher education, nonprofit organizations, state and local governments, and for-profit entities, to support ARL's mission of operationalizing science for military advancements. The BAA encompasses various research topics critical to Army modernization priorities, such as cyber-physical systems, artificial intelligence, and advanced learning-enabled intelligent systems, with a focus on improving soldier performance and operational capabilities in complex environments. Interested parties can find additional information and submit proposals via the ARL BAA topics website, with an expected number of awards totaling 2000 and no cost-sharing requirements. For inquiries, contact the U.S. Army Contracting Command at Aberdeen Proving Ground, or visit the ARL BAA topics website for further details.
    UNITED STATES ARMY RESEARCH INSTITUTE FOR THE BEHAVIORAL AND SOCIAL SCIENCES (ARI) BROAD AGENCY ANNOUNCEMENT FOR BASIC, APPLIED, AND ADVANCED SCIENTIFIC RESEARCH
    Active
    Dept of the Army -- Materiel Command
    The Department of the Army, through the United States Army Research Institute for the Behavioral and Social Sciences (ARI), has issued a Broad Agency Announcement (BAA) for Basic, Applied, and Advanced Scientific Research, effective from May 1, 2023, to April 30, 2028. This initiative aims to solicit proposals for research and development in areas such as personnel assessment, leadership development, team dynamics, and technology fluency, with a focus on enhancing Army readiness and performance through innovative approaches to talent management. Eligible applicants include institutions of higher education, non-profit organizations, and for-profit entities, while government entities are excluded from prime contracts. Interested parties should submit white papers to streamline the proposal process, with a total of approximately 1,000 awards expected. For further inquiries, applicants can contact Wilveria A. Sanders at wilveria.a.sanders.civ@army.mil, and proposals must be submitted by April 30, 2028.
    Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for small businesses to support the late-stage translation of biomedical and behavioral research results related to arthritis, musculoskeletal, and skin diseases into marketable products. This Small Business Innovation Research (SBIR) grant (PAR-23-032) aims to foster collaboration between academic/non-profit labs and small business concerns (SBCs) to advance diagnostics, treatments, and prevention tools, while specifically excluding clinical trials. The initiative is crucial for bridging laboratory discoveries with real-world applications, ultimately enhancing public health outcomes through medical innovations. Interested applicants can seek funding up to $350,000, with ongoing application cycles from January 2024 to September 2025, and should direct inquiries to grantsinfo@nih.gov for further information.